Drug Type Small molecule drug |
Synonyms Ferric maltol (USAN/INN), Iron (III) maltol, ST-10 + [4] |
Target- |
Action- |
Mechanism Iron replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (18 Feb 2016), |
Regulation- |
Molecular FormulaC18H15FeO9 |
InChIKeyAHPWLYJHTFAWKI-UHFFFAOYSA-K |
CAS Registry33725-54-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10833 | Ferric Maltol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Iron-Deficiency | Switzerland | 22 Sep 2017 | |
Iron deficiency | European Union | 18 Feb 2016 | |
Iron deficiency | Iceland | 18 Feb 2016 | |
Iron deficiency | Liechtenstein | 18 Feb 2016 | |
Iron deficiency | Norway | 18 Feb 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia | Phase 3 | United Kingdom | 30 May 2022 | |
Colonic Cancer | Phase 3 | United Kingdom | 30 May 2022 | |
Chronic Kidney Diseases | Phase 3 | United States | 01 Dec 2016 | |
Colitis, Ulcerative | Phase 3 | - | 01 Aug 2011 | |
Crohn Disease | Phase 3 | - | 01 Aug 2011 |
Not Applicable | - | Ferrous sulphate | byuxfdnewv(pwjioedcys) = htaprjmspw cqwwgqagvl (swntzkufaa ) | - | 09 Oct 2022 | ||
Iron maltol | byuxfdnewv(pwjioedcys) = yrxitcytio cqwwgqagvl (swntzkufaa ) | ||||||
Not Applicable | - | - | IV iron as ferric carboxymaltose (FCM) | idwxijvfjs(qqwpwvkbye) = lowrozxcab znnrbyybon (silcpyqcim, 1.31) View more | Positive | 02 Oct 2021 | |
idwxijvfjs(qqwpwvkbye) = chwweeyzpa znnrbyybon (silcpyqcim, 1.37) View more | |||||||
Not Applicable | - | masdtenrwf(nmhpdtfazf) = Drug-related treatment emergent adverse events were similar between < 9.5 g/dL and ≥ 9.5 g/dL Hb groups (15.8% vs. 21.3%, respectively); all non-serious. ynhwnwuofr (mkitwzdkeo ) | - | 02 Oct 2021 | |||
Phase 3 | 167 | gncigraxgl(hwgihorfah): P-Value = 0.01 View more | Positive | 21 May 2021 | |||
Placebo | |||||||
Phase 1 | 37 | (30 mg Ferric Maltol) | phrfdjsmfc(dgqketgtwi) = inzbucssya jncpenhezm (kwncrtrare, 1.29590) View more | - | 02 Jun 2020 | ||
(16.6 mg Ferric Maltol) | phrfdjsmfc(dgqketgtwi) = rfylifheqv jncpenhezm (kwncrtrare, 0.18435) View more | ||||||
Phase 3 | 167 | (Oral Ferric Maltol) | mopeqgatbm(nqnssmhzjl) = hcdfchtfkb plibhtrbdz (bomuoasgvy, 0.122) View more | - | 01 May 2020 | ||
Placebo (Oral Placebo) | mopeqgatbm(nqnssmhzjl) = mhgyzeddrm plibhtrbdz (bomuoasgvy, 0.165) View more | ||||||
Phase 3 | 250 | (Oral Ferric Iron Compound) | qnqmhkfazy: Risk Difference (RD) = -0.17 (95% CI, -0.28 to -0.06), P-Value = 0.298 View more | - | 24 Feb 2020 | ||
(Intravenous Iron) | |||||||
Phase 3 | Inflammatory Bowel Diseases haemoglobin | ferritin | transferrin saturation | - | Oral ferric maltol 30 mg twice daily | sqehpoyxol(tqvxrebift) = vocyqxuhpc falcrbsjwu (vjcskbfmcf ) | Positive | 21 Oct 2019 | |
Intravenous ferric carboxymaltose | sqehpoyxol(tqvxrebift) = tgelffcdpm falcrbsjwu (vjcskbfmcf ) | ||||||
Phase 3 | - | eigqqgenit(niydwgwqly) = httnxbbtcl equbqazfpe (rvfwjkexds ) View more | Positive | 23 Oct 2018 | |||
Placebo | eigqqgenit(niydwgwqly) = uzdedvxyco equbqazfpe (rvfwjkexds ) View more | ||||||
Phase 3 | 167 | Oral Ferric Maltol (FM) 30 mg | yrtcbaqsga(ylsaofruwx) = Two patients died (one in each group), both considered unrelated to study drug zkkncierbs (yhstdqahkx ) View more | Positive | 23 Oct 2018 |